
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About
Immuneering Corp (IMRX)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: IMRX (4-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $11.25
1 Year Target Price $11.25
2 | Strong Buy |
2 | Buy |
1 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 262.83% | Avg. Invested days 40 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 109.40M USD | Price to earnings Ratio - | 1Y Target Price 11.25 |
Price to earnings Ratio - | 1Y Target Price 11.25 | ||
Volume (30-day avg) 5 | Beta 0.37 | 52 Weeks Range 1.01 - 4.69 | Updated Date 08/15/2025 |
52 Weeks Range 1.01 - 4.69 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.9 |
Earnings Date
Report Date 2025-08-13 | When - | Estimate -0.42 | Actual -0.4 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -57.9% | Return on Equity (TTM) -102.48% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 87041596 | Price to Sales(TTM) 563.62 |
Enterprise Value 87041596 | Price to Sales(TTM) 563.62 | ||
Enterprise Value to Revenue 191913.54 | Enterprise Value to EBITDA -1.53 | Shares Outstanding 35985700 | Shares Floating 27205191 |
Shares Outstanding 35985700 | Shares Floating 27205191 | ||
Percent Insiders 24.35 | Percent Institutions 12.41 |
Upturn AI SWOT
Immuneering Corp
Company Overview
History and Background
Immuneering Corp. was founded in 2008. It's a biopharmaceutical company focusing on developing and commercializing transformative therapies to treat cancer patients.
Core Business Areas
- Drug Development: Developing new therapies based on biological insights and computational approaches.
Leadership and Structure
Executive leadership includes Diana Brainard, M.D. as CEO. Organizational structure is typical of a clinical-stage biotech firm, with departments focused on research, development, clinical trials, and business operations.
Top Products and Market Share
Key Offerings
- IMM-1-104: An oral MEK inhibitor being developed for advanced RAS mutant solid tumors. Phase 1/2a clinical trials are ongoing. No current market share as it is still in development. Competitors include other MEK inhibitors in development.
Market Dynamics
Industry Overview
The pharmaceutical industry, specifically oncology, is characterized by high R&D costs, long development timelines, and stringent regulatory requirements. There is a large unmet need for novel cancer therapies.
Positioning
Immuneering is positioned as a targeted oncology drug developer, aiming to address specific unmet needs in RAS mutant solid tumors. Competitive advantages include their unique computational approach to drug discovery.
Total Addressable Market (TAM)
The global market for cancer therapies is estimated at hundreds of billions of dollars. Immuneering is focusing on subsets of this market, particularly RAS mutant cancers. The specific TAM for their drug candidates will depend on the successful completion of clinical trials and subsequent regulatory approvals.
Upturn SWOT Analysis
Strengths
- Novel computational drug discovery platform
- Experienced management team
- Promising pre-clinical and clinical data
- Targeting specific unmet medical needs
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Reliance on successful clinical trial outcomes
- High risk of drug development failure
- Single product pipeline
Opportunities
- Potential partnerships with larger pharmaceutical companies
- Expansion of pipeline into other oncology indications
- Positive clinical trial results leading to regulatory approval
- Advancements in computational drug discovery
Threats
- Clinical trial failures
- Competition from other pharmaceutical companies
- Changes in regulatory landscape
- Intellectual property challenges
- Economic downturn affecting investment in biotechnology
Competitors and Market Share
Key Competitors
- ARRY
- RDHL
- TAK
Competitive Landscape
Immuneering faces competition from established pharmaceutical companies and other biotech firms developing oncology therapies. Their computational platform offers a potential advantage, but clinical trial success is crucial.
Growth Trajectory and Initiatives
Historical Growth: Immuneering's historical growth is characterized by progress in pre-clinical and early clinical development. Revenue growth is not a primary focus at this stage.
Future Projections: Future growth depends on successful clinical trial outcomes for IMM-1-104 and other pipeline candidates. Analyst estimates are available from financial news sources and research reports.
Recent Initiatives: Recent initiatives include advancing IMM-1-104 through clinical trials and exploring new drug targets using their computational platform.
Summary
Immuneering Corp is a high-risk, high-reward clinical-stage biopharmaceutical company. The company has a unique computational platform for drug discovery. Their success hinges on the outcomes of clinical trials, particularly for IMM-1-104. The company needs to manage its cash burn rate and secure further funding. Potential partnerships can further de-risk development.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Financial news sources
- Analyst reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual risk tolerance and thorough research.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Immuneering Corp
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2021-07-30 | Co-Founder, President, CEO & Director Dr. Benjamin J. Zeskind M.B.A., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 54 | Website https://immuneering.com |
Full time employees 54 | Website https://immuneering.com |
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 that is in Phase 1/2a clinical trial for the treatment of patients with solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.